초록 ▼

The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used

The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

대표청구항 ▼

1. A composition for imaging comprising: a) a radionuclide label; b) ethylenedicysteine; and c) a tissue specific ligand conjugated to said ethylenedicysteine, wherein the tissue specific ligand is an anticancer agent, a folate receptor targeting ligand, a tumor apoptotic cell targeting ligand,

1. A composition for imaging comprising: a) a radionuclide label; b) ethylenedicysteine; and c) a tissue specific ligand conjugated to said ethylenedicysteine, wherein the tissue specific ligand is an anticancer agent, a folate receptor targeting ligand, a tumor apoptotic cell targeting ligand, a tumor hypoxia cell targeting ligand or glutamate pentapeptide; and wherein said ethylenedicysteine forms an N2S2chelate with said radionuclide label. 2. The composition of claim 1, wherein said tissue specific ligand may be conjugated to said ethylenedicysteine on one or both acid arms of the ethylenedicysteine. 3. The composition of claim 1, wherein said radionuclide is 99mTc, 188Re, 186Re, 183Sm, 166Ho, 90Y, 89Sr, 67Ga, 68Ga, 111In, 183Gd, 59Fe, 225Ac, 212Bi, 211At, 64Cu or 62Cu. 4. The composition of claim 3, wherein said radionuclide is 99mTc. 5. The composition of claim 1, wherein said tissue specific ligand is an anticancer agent. 6. The composition of claim 5, wherein said anticancer agent may be selected from the group consisting of methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine and tomudex. 7. The composition of claim 1, wherein the tissue specific ligand is a folate receptor targeting ligand. 8. The composition of claim 7, wherein the folate receptor targeting ligand is folate, methotrexate or tomudex. 9. The composition of claim 8, further defined as 99mTc-EC-folate. 10. The composition of claim 8, further defined as 99mTc-EC-methotrexate. 11. The composition of claim 8, further defined as 99mTc-EC-tomudex. 12. The composition of claim 1, wherein the tissue specific ligand is a tumor apoptotic cell targeting ligand or a tumor hypoxia targeting ligand. 13. The composition of claim 11, wherein the tissue specific ligand is annexin V, colchicine, nitroimidazole, mitomycin or metronidazole. 14. The composition of claim 12, further defined as 99mTc-EC-annexin V. 15. The composition of claim 12, further defined as 99mTc-EC-colchicine. 16. The composition of claim 12, further defined as 99mTc-EC-nitroimidazole. 17. The composition of claim 12, further defined as 99mTC-EC-metronidas. 18. The composition of claim 1, wherein the tissue specific ligand is glutamate pentapeptide. 19. The composition of claim 17, further defined as 99m Tc-EC-glutamate pentapeptide. 20. The composition of claim 1, further comprising a linker conjugating EC to said tissue specific ligand. 21. The composition of claim 19, wherein the linker is a water soluble peptide, glutamic acid, aspartic acid, bromo ethylacetate, ethylene diamine or lysine. 22. The composition of claim 20, wherein the tissue specific ligand is estradiol, topotecan, paclitaxel, raloxifen, etoposide, doxorubicin, mitomycin C, endostatin, annexin V, LHRH, octreotide, VIP, methotrexate or folic acid.